Atrial fibrillation (AF) and intermittent fasting is a topic of growing interest, particularly as more people with AF look to lifestyle changes to support their heart health. AF affects an estimated 1.4 million people in the UK and is closely linked to modifiable risk factors such as obesity, hypertension, and metabolic dysfunction — all areas where intermittent fasting may offer potential benefits. However, the evidence is still evolving, and fasting carries specific safety considerations for those managing AF and its associated medications. This article explores what the current research shows, what precautions to take, and when to seek medical advice.

What Is Atrial Fibrillation and How Is It Managed in the UK?

AF is the UK's most common sustained cardiac arrhythmia, managed with anticoagulation (typically DOACs), rate or rhythm control, and lifestyle modification targeting risk factors such as obesity and hypertension.

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the UK, affecting an estimated 1.4 million people. It occurs when the electrical signals coordinating the heartbeat become chaotic, causing the atria (the upper chambers of the heart) to quiver irregularly rather than contract effectively. This can lead to symptoms including palpitations, breathlessness, fatigue, and dizziness, though some individuals remain entirely asymptomatic.

The condition carries significant clinical implications. People with AF have a fivefold increased risk of stroke, largely due to the formation of blood clots within the left atrial appendage.^[2] NICE guidance (NG196) recommends using the CHA₂DS₂-VASc scoring tool to assess stroke risk and guide anticoagulation therapy.^[3][4] Bleeding risk should also be formally assessed — NICE NG196 recommends the ORBIT tool for this purpose — and should be reviewed alongside stroke risk before anticoagulation is initiated or continued.^[3][4]

Direct oral anticoagulants (DOACs) — including apixaban, rivaroxaban, edoxaban, and dabigatran — are generally preferred over warfarin for most people with AF, unless a DOAC is contraindicated or not tolerated.^[3][4] Warfarin remains appropriate in selected cases, such as those with mechanical heart valves or significant renal impairment.

Management of AF in the UK typically follows two broad strategies:

• Rate control: Slowing the ventricular rate using beta-blockers (e.g., bisoprolol), rate-limiting calcium channel blockers (e.g., diltiazem), or digoxin.

• Rhythm control: Restoring and maintaining normal sinus rhythm through cardioversion, antiarrhythmic drugs (e.g., flecainide, amiodarone), or catheter ablation.

Lifestyle modification is also a cornerstone of AF management. NICE NG196 and the British Heart Foundation highlight the importance of managing modifiable risk factors as part of a comprehensive care plan. These include obesity, hypertension, excessive alcohol consumption, physical inactivity, thyroid disease, and obstructive sleep apnoea. It is within this lifestyle context that interest in dietary approaches such as intermittent fasting has grown.

What Is Intermittent Fasting and Who Practises It?

Intermittent fasting cycles between defined eating and fasting periods — common protocols include 16:8 and 5:2 — and is used by people managing weight, metabolic conditions, and cardiovascular risk factors.

Intermittent fasting (IF) is an umbrella term for dietary patterns that cycle between defined periods of eating and fasting. Unlike traditional calorie-restricted diets, IF focuses primarily on when food is consumed rather than exclusively what is eaten. Several protocols have gained popularity in the UK and internationally:

• 16:8 method: Eating within an 8-hour window and fasting for 16 hours each day.

• 5:2 diet: Eating normally for five days per week and restricting calorie intake to approximately 500–600 kcal on two non-consecutive days.

• Alternate-day fasting (ADF): Alternating between normal eating days and fasting or very low-calorie days.

IF has attracted interest across a broad demographic, from individuals seeking weight loss to those managing metabolic conditions such as type 2 diabetes, hypertension, and dyslipidaemia. Some research suggests potential benefits including improvements in insulin sensitivity, blood pressure, inflammatory markers, and body weight — all of which are relevant to cardiovascular health — though the evidence base is still evolving and findings are not consistent across all studies.

NICE supports personalised, sustainable approaches to energy restriction for weight management. IF may be an acceptable strategy for certain individuals if it is safe and patient-preferred, but it is not specifically endorsed as a named dietary approach in NICE guidance. Suitability depends heavily on an individual's medical history, medications, and overall health status.

IF is not appropriate for everyone. People who should avoid fasting, or only fast under close medical supervision, include those who are pregnant or breastfeeding, underweight, living with an eating disorder, frail or older adults at risk of malnutrition, those with type 1 diabetes, advanced chronic kidney disease, or decompensated heart failure.

For people living with AF, the intersection of fasting and cardiac health raises important questions. Many individuals with AF are also managing comorbidities such as obesity, hypertension, or type 2 diabetes — conditions for which IF may offer metabolic benefits. Understanding the evidence base, however, is essential before making any dietary changes.

What the Current Evidence Says About AF and Fasting

Current evidence neither definitively supports nor condemns intermittent fasting for people with AF; potential cardioprotective metabolic benefits exist, but large-scale randomised trials in AF populations are lacking.

The relationship between intermittent fasting and atrial fibrillation is an emerging area of research, and the evidence base remains limited and at times conflicting. Robust, large-scale randomised controlled trials specifically examining IF in AF populations are currently lacking.

One widely cited observational analysis, presented at the American Heart Association Scientific Sessions in 2024 and based on US National Health and Nutrition Examination Survey (NHANES) data, suggested that individuals reporting a time-restricted eating pattern had a higher rate of cardiovascular death compared with those eating across a broader daily window. This finding generated considerable media attention. However, it is important to note that this was an observational study with significant methodological limitations, including reliance on self-reported dietary data collected over only one to two days, and it was not conducted specifically in people with AF.^[7][6] There is no established causal link between intermittent fasting and increased cardiovascular mortality, and the findings should be regarded as hypothesis-generating only, pending replication in prospective trials.

Conversely, other research — including systematic reviews and meta-analyses — has highlighted potential cardioprotective effects of IF. Studies have demonstrated reductions in:

• Body weight and BMI — obesity being a well-established risk factor for AF.^[24]

• Blood pressure — hypertension is a major driver of AF progression.

• Inflammatory markers such as C-reactive protein (CRP), which are implicated in atrial remodelling.

• Insulin resistance — metabolic dysfunction is increasingly linked to arrhythmia risk.

It is worth noting that some meta-analyses suggest the metabolic advantages of time-restricted eating over conventional calorie restriction alone may be modest, and that adherence and individual response vary considerably.^[8][9]

Some small studies have also explored Ramadan fasting — a form of prolonged daily fasting — in stable patients with cardiac conditions, with generally reassuring short-term outcomes.^[23] These findings apply specifically to clinically stable individuals who have had their medications reviewed and adjusted in advance by their healthcare team, and should not be generalised to all people with AF.

Overall, the current evidence neither definitively supports nor condemns IF for people with AF. Clinicians and patients should interpret emerging data carefully and await further high-quality research before drawing firm conclusions.

Safety Considerations for People With AF Considering Fasting

Key safety concerns include maintaining consistent DOAC timing, monitoring for electrolyte imbalances that can trigger arrhythmias, avoiding dehydration, and managing hypoglycaemia risk in those with diabetes.

For individuals living with AF who are considering intermittent fasting, several important safety considerations must be addressed before making any dietary changes. These relate not only to the arrhythmia itself but also to the medications commonly used in its management.

Anticoagulation and medication timing is a primary concern. Many people with AF take DOACs, which must be taken at consistent times each day to maintain stable anticoagulation. Some DOACs must be taken with food: rivaroxaban (Xarelto), for example, should be taken with food at the same time each day to optimise absorption — the specific meal timing should follow the prescriber's or pharmacist's advice and the product's Summary of Product Characteristics (SmPC).^[13][14] Apixaban and dabigatran are taken twice daily; edoxaban and rivaroxaban are taken once daily.^[3][5] Fasting windows must not compromise adherence to these schedules. Those taking warfarin should be aware that significant dietary changes can influence INR stability, and are advised to arrange more frequent INR checks with their anticoagulation clinic when starting or substantially changing an IF regimen. The NHS provides specific guidance on food and drink interactions with warfarin.

Electrolyte imbalances represent another consideration. Prolonged or very low-calorie fasting, particularly in combination with diuretics, significant dehydration, or gastrointestinal losses, may contribute to reductions in potassium, magnesium, and sodium. Hypokalaemia and hypomagnesaemia are known triggers for arrhythmias, including AF.^[18] Individuals on diuretics — commonly prescribed for heart failure or hypertension alongside AF — should be aware of this heightened risk and ensure adequate fluid and electrolyte intake.

Additional considerations include:

• Dehydration: Inadequate fluid intake during fasting windows can cause symptoms such as dizziness, light-headedness, and palpitations, and may worsen haemodynamic stability. Maintaining good hydration throughout the day is important.

• Hypoglycaemia risk: Those with comorbid type 2 diabetes managed with insulin or sulphonylureas face a risk of low blood sugar during fasting periods. People taking SGLT2 inhibitors should be aware of the risk of euglycaemic diabetic ketoacidosis (DKA) during fasting or very low-carbohydrate eating — this should be discussed with a diabetes specialist or GP before commencing IF.^[19][20] Diabetes UK provides specific guidance on fasting and medication adjustments.

• Vagal triggers: Some individuals find that hunger, dehydration, or large post-fast meals can trigger AF episodes via vagal stimulation.

Groups who should not fast without close medical supervision include those who are pregnant or breastfeeding, underweight, living with an eating disorder, frail older adults, those with type 1 diabetes, advanced chronic kidney disease, or decompensated heart failure.

If you suspect that a medicine is causing side effects, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Any dietary intervention should be discussed with a healthcare professional before commencement, particularly for those with complex, unstable, or recently treated AF.

When to Seek Medical Advice From Your GP or Cardiologist

Anyone with AF should speak to their GP or cardiologist before starting intermittent fasting; call 999 immediately for stroke symptoms, chest pain, or severe palpitations.

If you have been diagnosed with atrial fibrillation and are considering intermittent fasting, the most important first step is to speak with your GP or cardiologist before making any changes to your diet. This is especially important if your AF is poorly controlled, if you have recently undergone cardioversion or ablation, or if you are managing multiple comorbidities alongside your heart condition.

Call 999 immediately if you or someone else experiences symptoms that may indicate a stroke or TIA. Use the FAST test:

• Face — has one side of the face drooped or become numb?

• Arms — can both arms be raised, or is one weak?

• Speech — is speech slurred, confused, or difficult to understand?

• Time — time to call 999 immediately if any of these signs are present.

You should also seek prompt medical advice if you experience any of the following whilst fasting:

• New or worsening palpitations, a racing or irregular heartbeat, or episodes of AF that feel more frequent or prolonged than usual.

• Dizziness, light-headedness, or fainting, which may indicate dehydration, electrolyte imbalance, or haemodynamic compromise.

• Chest pain or tightness, which should always be treated as a potential cardiac emergency — call 999 if symptoms are severe or you are in any doubt.

• Unusual bruising or bleeding, which may suggest a change in anticoagulant effect, particularly relevant for those on warfarin whose INR may fluctuate with dietary changes.

• Symptoms of hypoglycaemia in those with diabetes, including shakiness, sweating, confusion, or extreme hunger.

For urgent concerns that are not immediately life-threatening, contact NHS 111 for advice.

Your GP can review your current medications, assess whether IF is appropriate given your individual risk profile, and refer you to a cardiologist or dietitian if needed. If you take warfarin, inform your anticoagulation or INR clinic of any planned dietary changes so that monitoring frequency can be adjusted accordingly. NHS cardiac rehabilitation services and structured weight management programmes may also offer supervised dietary support for people with cardiovascular conditions.

Ultimately, whilst intermittent fasting may offer metabolic benefits relevant to AF risk factors, it is not a one-size-fits-all approach. Personalised medical guidance remains essential. Making informed, evidence-based decisions in partnership with your healthcare team is the safest and most effective path forward.

Frequently Asked Questions